Finance

Lists
Why is ARQT up 11.49%?
Dive Deeper
ARQT:NASDAQ
Arcutis Biotherapeutics Inc
$32.13
+11.49%
(+3.31) 1D
Oct 19, 12:41:21 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ARQT...
Open
$29.41
High
$32.24
Low
$28.99
Mkt. cap
4.04B
Avg. vol.
3.10M
Volume
2.30M
P/E ratio
149.78
52-wk high
$32.24
52-wk low
$19.30
EPS
$0.21
Beta
1.57
Shares outstanding
125.69M
No. of employees
354
Open
$29.41
High
$32.24
Low
$28.99
Mkt. cap
4.04B
Avg. vol.
3.10M
Volume
2.30M
P/E ratio
149.78
52-wk high
$32.24
52-wk low
$19.30
EPS
$0.21
Beta
1.57
Shares outstanding
125.69M
No. of employees
354
News stories
From web sources and news partners
About Arcutis Biotherapeutics Inc
CEOFrank Watanabe
Employees354
Founded2016
HeadquartersWestlake Village, California, United States
SectorBiotechnology
Websitearcutis.com
Analyst ratings
Based on 6 analysts giving stock ratings to ARQT in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for ARQT in the last 3 months.
Highest
Current $32.13
$48.00 (+49.39%)
Average
$39.83 (+23.97%)
Lowest
$34.00 (+5.82%)
Analyst
Recommendation
Action
Price target
Projected
Date
Seamus Fernandez
Guggenheim
Buy
Reiterated
$44.00
+36.9%
10/19/2026
Steven Seedhouse
Cantor Fitzgerald
Buy
Initiated
$48.00
+49.4%
10/15/2026
Douglas Tsao
H.C. Wainwright
Buy
Reiterated
$34.00
+5.8%
08/10/2026
Judah Frommer
Morgan Stanley
Buy
Reiterated
$38.00
+18.3%
08/06/2026
Serge Belanger
Needham
Buy
Reiterated
$40.00
+24.5%
08/06/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
$35.00
+8.9%
08/05/2026
Uy Ear
Mizuho Securities
Buy
Reiterated
$36.00
+12%
08/06/2026
Unknown Analyst
Guggenheim
Buy
Reiterated
$35.00
+8.9%
07/16/2026
Unknown Analyst
Jefferies
Buy
Maintained
$35.00
+8.9%
07/09/2026
Richard Law CFA
Goldman Sachs
Hold
Maintained
$33.00
+2.7%
02/27/2026
Last report
Aug 5, 2026
Fiscal period
Q2 2026
$0.11 / $0.05
+120.00%beat
Revenue / Est. (USD)
129.86M / 118.85M
+9.26%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
99.22M
129.50M
105.40M
129.86M
Cost of goods sold
8.68M
11.69M
9.78M
10.94M
Cost of revenue
8.68M
11.69M
9.78M
10.94M
Research and development expenses
19.60M
20.45M
30.63M
20.36M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
62.40M
78.98M
74.08M
82.14M
Operating expense
82.01M
99.43M
104.70M
102.49M
Total operating expenses
90.69M
111.12M
114.49M
113.43M
Operating income
8.53M
18.39M
-9.09M
16.43M
Other non operating income
-
443.00K
-20.00K
-157.00K
EBT including unusual items
7.49M
17.86M
-11.20M
15.14M
EBT excluding unusual items
7.49M
17.86M
-11.20M
15.14M
Income tax expense
80.00K
470.00K
93.00K
136.00K
Effective tax rate
1.07%
2.63%
-0.83%
0.90%
Other operating expenses
-
-
-
-
Net income
7.41M
17.40M
-11.30M
15.01M
Net profit margin
7.47%
13.43%
-10.72%
11.56%
Earnings per share
0.06
0.13
-0.09
0.11
Interest and investment income
2.04M
2.04M
2.28M
2.28M
Interest expense
-3.07M
-3.00M
-4.37M
-3.41M
Net interest expenses
-1.04M
-965.00K
-2.09M
-1.13M
Depreciation and amortization charges
-
-
-
-
EBITDA
9.09M
18.95M
-8.53M
16.99M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps